The client challenge
Some air-treatment products arrive at the lab as finished devices. Glow Guardian was different. The product began as a functional candle concept designed not only to burn, but to release active constituents into room air and reduce viable airborne microorganisms under controlled test conditions.1,3,4
That made the development question unusual. A filter-based purifier pulls air through media, a ducted system treats air in an HVAC path, and an in-device treatment system acts inside a housing. Glow Guardian's concept was active-in-air: the product was intended to release constituents into the room air where they could interact with airborne microorganisms.1,3
Glow Guardian needed more than a routine pass/fail test. The client needed a development pathway that connected aerosol science, formulation refinement, bioaerosol generation, viable sampling, chamber testing, and data interpretation.1
ARE Labs as development partner
ARE Labs assisted Glow Guardian through formulation support, chamber challenge testing, method adaptation, and final efficacy studies. A candle formulation would be evaluated, the bioaerosol response would be measured, and the formulation would be adjusted. That cycle repeated many times as the team worked toward a final product configuration.1
The repeated challenge process mattered because active-in-air products are sensitive to mechanism and method fit. Small changes in formulation, release behavior, burn characteristics, particle behavior, or active delivery can affect performance. The chamber became a feedback tool rather than just a final reporting environment.1,2
How the product was tested
The primary efficacy study evaluated the Glow Guardian air treatment candle against a broad range of respirable microorganisms in a sealed environmental bioaerosol test chamber. The source report states that the work followed a protocol modeled on FDA 510(k)-style in-room air purifier testing methods and complied with Good Laboratory Practice expectations in 21 CFR Part 58.1,5
Each microorganism was aerosolized into a controlled chamber containing the candle. ARE Labs used controlled bioaerosol generation, viable sampling, serial dilution, plating, incubation, and enumeration to quantify viable bioaerosol concentrations over time. Natural chamber decay was measured through control trials and subtracted from candle trials to calculate net reduction.1
| Organism or surrogate | Organism type | Maximum net percent reduction | Average CADR |
|---|---|---|---|
| MS2 bacteriophage | Unenveloped RNA virus surrogate | 99.74% | 35.40 cfm |
| Phi X bacteriophage | Unenveloped DNA virus surrogate | 99.15% | 24.05 cfm |
| Staphylococcus epidermidis | Gram-positive bacterium | 99.93% | 35.29 cfm |
| Listeria innocua | Gram-positive bacterium | 99.97% | 35.87 cfm |
| Klebsiella aerogenes | Gram-negative bacterium | 99.99% | 46.17 cfm |
| Pseudomonas syringae | Gram-negative bacterium | 99.78% | 47.32 cfm |
| Aspergillus brasiliensis | Mold spores | 81.84% | 12.23 cfm |
| Bacillus subtilis | Bacterial endospores | 34.84% | 3.53 cfm |
Broad-spectrum results
The final broad-range study showed measurable efficacy across all organism groups tested. Against most non-spore organisms, the Glow Guardian candle achieved greater than 99% maximum net percent reduction over the two-hour chamber test period after control correction. More resistant organisms, including mold spores and bacterial endospores, showed lower reductions.1
Source: client-approved ARE Labs broad-range bioaerosol efficacy report summary.
- Organism names are shortened in the chart labels for readability.
- Values are control-corrected maximum net percent reductions from the source article.
The organism-dependent pattern strengthened the technical story because it avoided treating every biological challenge as equivalent. Gram-negative bacteria and virus surrogates showed high reductions. Mold spores and bacterial endospores were more resistant, which is consistent with their greater environmental durability.1
The first-minute question
A second question emerged because the product category was active-in-air: what happens immediately after a bioaerosol enters a room that has already been pretreated? For filtration, in-device UV, and many recirculating air cleaners, contaminated air generally must travel into the device or treatment zone. If active material is already distributed in the room, the early-event behavior may matter.2
ARE Labs evaluated that scenario in a separate pretreatment study. The candle was lit before bioaerosol introduction, organisms were aerosolized into the chamber after a defined pretreatment period, and viable concentrations were measured after one minute of chamber mixing.2
| Pretreatment challenge organism | Organism type | Net percent reduction after one minute |
|---|---|---|
| MS2 bacteriophage | Unenveloped RNA virus surrogate | 90.66% |
| Klebsiella aerogenes | Gram-negative bacterium | 41.75% |
| Staphylococcus epidermidis | Gram-positive bacterium | 30.80% |
The pretreatment study is summarized here because it shaped the active-in-air method story.
Business impact
The outcome for Glow Guardian was not just a test report. By the end of the program, the client had a functional candle formulation advanced from concept toward product readiness, broad-range viable bioaerosol efficacy data, one-minute room-pretreatment data, and a public-facing science story supported by independent laboratory reports.1,2,3
For buyers, partners, retailers, and investors, that distinction matters. A novel consumer-facing air-treatment product needs more than a simple claim that it works. It needs evidence that the mechanism can be challenged, measured, repeated, and explained in language that stays within the boundaries of the test data.1,3
The public patent record also identifies U.S. Patent No. 12,467,016 B1, titled Air purification candle, assigned to Glow Guardian. That patent context matters to the success story because the lab work, product-development loop, and public IP record all point to the same broader outcome: a novel product moved from concept into a documented technical position.4
What this says about method fit
Many labs can run a standard method. Fewer labs can help a client develop a product when the method itself needs to be adapted to the product's mechanism. Glow Guardian's development required aerosol generation, viable bioaerosol sampling, chamber design, particle behavior, formulation support, and GLP-aligned reporting to work together.1,5
That is the broader lesson for aerosol and air-treatment developers. If the product depends on airborne actives, room-scale interaction, or nontraditional release behavior, the testing plan should be built around how the product is meant to work, not around the closest familiar test category. Otherwise, useful development signals can be missed or misread.1,2
Summary
In summary, Glow Guardian needed more than final validation; the client needed a development partner that could test, interpret, and refine a novel active-in-air product concept. ARE Labs supported the work by connecting formulation iteration, room-scale bioaerosol challenge methods, control-corrected efficacy data, and careful claim boundaries into a public success story backed by measured evidence.1,2